Viking Therapeutics Inc
Viking Therapeutics Inc is a biotechnology company operating within the Health Care sector, currently generating no revenue while incurring significant operating losses.
Business. Viking Therapeutics Inc (VKTX.O) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
20 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
2Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Viking Therapeutics Inc (VKTX.O) experienced a major shift in holder activity, with investor ID 587 significantly adjusting their position. Data detected on June 23, 2026, shows this investor increased their holdings to 7,654 shares, valued at approximately $0.25 million, as of March 31, 2026. This represents a substantial increase from a prior holding of 302 shares. However, a subsequent signal detected on June 21, 2026, indicates a reversal or correction in the data, showing the position returning to 302 shares, highlighting volatility or reporting adjustments in this specific holder's stake. Concurrently, the company's risk profile has been updated with new assessments. Both dilution risk and liquidity risk have been classified as "low," a change from no prior classification. These assessments were determined based on specific threshold criteria, suggesting that despite the holder activity, the immediate financial risks related to share dilution and market liquidity are currently viewed as minimal by the analysis framework. The company's classification status also saw changes, with both its activity and economic sector taxonomy fields updated to "Unclassified." This change, marked with medium severity, indicates a lack of specific categorization in the current data model, which may affect how the stock is grouped in broader sector analyses. Additionally, the AI analysis narrative was revised, though the specific details of the narrative change are not fully disclosed in the available facts. In terms of broader market attention, news dispatch activity has been sparse. Over the period from late June to mid-July 2026, there was only one dispatch recorded on June 30, with zero activity on surrounding days. This low volume of news flow, combined with the company having zero analyst coverage and no index memberships, suggests limited current market scrutiny. The company maintains a base of 30 top holders, providing a foundation of institutional interest despite the recent specific holder fluctuations.
Signals & dispatch
Composite-score breakdown
Synthesis
Viking Therapeutics Inc (VKTX.O) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Viking Therapeutics maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet shows total assets of $715.7 million against total liabilities of $76.7 million, leaving total equity at $639.1 million. Cash and equivalents stand at $165.8 million, providing a liquidity buffer against the negative operating cash flow of $278.7 million. The current ratio is not explicitly provided, but the high cash position relative to liabilities suggests adequate short-term solvency despite the burn rate.
Profitability metrics are deeply negative, reflecting the pre-revenue stage of the business. Return on equity is -56.3% and return on assets is -50.3%, driven by an operating income of -$393.3 million and net income of -$359.6 million. With zero revenue, traditional margin analysis is not applicable. The company is burning cash to fund operations, likely research and development, without any offsetting sales.
Viking Therapeutics Inc (VKTX.O) experienced a major shift in holder activity, with investor ID 587 significantly adjusting their position. Data detected on June 23, 2026, shows this investor increased their holdings to 7,654 shares, valued at approximately $0.25 million, as of March 31, 2026. This represents a substantial increase from a prior holding of 302 shares. However, a subsequent signal detected on June 21, 2026, indicates a reversal or correction in the data, showing the position returning to 302 shares, highlighting volatility or reporting adjustments in this specific holder's stake. Concurrently, the company's risk profile has been updated with new assessments. Both dilution risk and liquidity risk have been classified as "low," a change from no prior classification. These assessments were determined based on specific threshold criteria, suggesting that despite the holder activity, the immediate financial risks related to share dilution and market liquidity are currently viewed as minimal by the analysis framework. The company's classification status also saw changes, with both its activity and economic sector taxonomy fields updated to "Unclassified." This change, marked with medium severity, indicates a lack of specific categorization in the current data model, which may affect how the stock is grouped in broader sector analyses. Additionally, the AI analysis narrative was revised, though the specific details of the narrative change are not fully disclosed in the available facts. In terms of broader market attention, news dispatch activity has been sparse. Over the period from late June to mid-July 2026, there was only one dispatch recorded on June 30, with zero activity on surrounding days. This low volume of news flow, combined with the company having zero analyst coverage and no index memberships, suggests limited current market scrutiny. The company maintains a base of 30 top holders, providing a foundation of institutional interest despite the recent specific holder fluctuations.
- Zero revenue and significant net loss of $359.6 million characterize the current financial period.
- Strong balance sheet with $165.8 million in cash and zero debt provides operational runway.
- Analyst sentiment is positive with a mean recommendation of 1.75 and mean price target of $93.22.
- Low dilution and liquidity risks are flagged, though cash burn remains a key operational metric.
- Classification confidence is low (0.20), requiring careful interpretation of sector benchmarks.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -4,80 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -585,8M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 190 000 @ $31,27grant · 2026-06-01
- Chief Commercial Officer · Stock Option (Right to Buy) → Common StockAcquired 180 000 @ $31,76grant · 2026-01-12
- Director · Stock Option (Right to Buy) → Common StockAcquired 20 400 @ $35,42grant · 2026-01-02
- Chief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 91 000 @ $35,42grant · 2026-01-02
- Chief Operating Officer · Stock Option (Right to Buy) → Common StockAcquired 91 000 @ $35,42grant · 2026-01-02
- Director, President & CEO · Stock Option (Right to Buy) → Common StockAcquired 176 300 @ $35,42grant · 2026-01-02
- Director · Stock Option (Right to Buy) → Common StockAcquired 20 400 @ $35,42grant · 2026-01-02
- Director · Stock Option (Right to Buy) → Common StockAcquired 20 400 @ $35,42grant · 2026-01-02
- Director · Stock Option (Right to Buy) → Common StockAcquired 20 400 @ $35,42grant · 2026-01-02
- Director · Stock Option (Right to Buy) → Common StockDisposed 16 000 @ $3,33exercise · 2026-01-02
- Director · Stock Option (Right to Buy) → Common StockAcquired 20 400 @ $35,42grant · 2026-01-02
- Director · Stock Option (Right to Buy) → Common StockDisposed 22 000 @ $5,80exercise · 2025-10-27
- Director · Stock Option (Right to Buy) → Common StockDisposed 16 000 @ $4,48exercise · 2025-10-27
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Cash Conversion Ratiooperating_cash_flow / net_income
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Return On Equitynet_income / total_equity
- Return On Assetsnet_income / total_assets
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- VIKING THERAPEUTICS, INC. Market data — financials · 2026-06-25
- ha_refusal_refire fired on VKTX.O · 2026-06-25
- Viking Therapeutics Inc Market data — analyst estimates · 2026-06-25
- Viking Therapeutics Inc Market data — ESG · 2026-06-25
Ownership & reference
Top holders
- Brokerage Firms · as of 2026-03-310,04 %$114M
- Investment Managers · as of 2026-03-310,03 %$68M
- Institutional Investor · as of 2026-03-310,01 %$55M
- Institutional Investor · as of 2026-03-310,01 %$196M
- Investment Managers · as of 2026-03-310,01 %$17M
- Investment Managers · as of 2026-03-310,01 %$44M
- Investment Managers · as of 2024-06-300,01 %$319M
- Investment Managers · as of 2026-03-310,01 %$98M
- Investment Managers · as of 2025-12-310,01 %$351M
- Investment Managers · as of 2026-03-310,00 %$143M
- Investment Managers · as of 2026-03-310,00 %$68M
- Investment Managers · as of 2026-03-310,00 %$31M
- Investment Managers · as of 2026-03-310,00 %$18M
- Investment Managers · as of 2026-03-310,00 %$24M
- Investment Managers · as of 2024-12-310,00 %$13M
- Institutional Investor · as of 2026-03-310,00 %$15M
- Investment Managers · as of 2026-03-310,00 %$19M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$6M
- Brokerage Firms · as of 2026-03-310,00 %$4M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Funds · as of 2026-03-310,00 %$4M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- Chief Financial Officer · Common Stock, par value $0.00001 per shareSold 21 217 @ $33,47$710K · 2026-07-29
- Director, President & CEO · Common Stock, par value $0.00001 per shareSold 148 517 @ $33,32$4,9M · 2026-07-29
- Chief Operating Officer · Common Stock, par value $0.00001 per shareSold 18 217 @ $33,47$610K · 2026-07-29
- Director, President & CEO · Common Stock, par value $0.00001 per shareOther 221 667 · 2026-07-28
- Chief Operating Officer · Common Stock, par value $0.00001 per shareOther 31 667 · 2026-07-28
- Chief Financial Officer · Common Stock, par value $0.00001 per shareOther 31 667 · 2026-07-28
- Chief Commercial Officer · Common Stock, par value $0.00001 per shareBought 4 475 @ $33,50$150K · 2026-03-10
- Director, President & CEO · Common Stock, par value $0.00001 per shareSold 41 276 @ $34,22$1,4M · 2026-01-05
- Director, President & CEO · Common Stock, par value $0.00001 per shareSold 6 400 @ $35,07$224K · 2026-01-05
- Director, President & CEO · Common Stock, par value $0.00001 per shareSold 53 279 @ $33,38$1,8M · 2026-01-05
- Director, President & CEO · Common Stock, par value $0.00001 per shareSold 132 454 @ $32,29$4,3M · 2026-01-05
- Chief Operating Officer · Common Stock, par value $0.00001 per shareSold 1 600 @ $35,07$56K · 2026-01-05
- Chief Operating Officer · Common Stock, par value $0.00001 per shareSold 10 500 @ $34,22$359K · 2026-01-05
- Chief Operating Officer · Common Stock, par value $0.00001 per shareSold 13 600 @ $33,37$454K · 2026-01-05
- Chief Operating Officer · Common Stock, par value $0.00001 per shareSold 31 961 @ $32,29$1,0M · 2026-01-05
- Chief Financial Officer · Common Stock, par value $0.00001 per shareSold 1 500 @ $32,09$48K · 2026-01-05
- Chief Financial Officer · Common Stock, par value $0.00001 per shareSold 10 300 @ $34,24$353K · 2026-01-05
- Chief Financial Officer · Common Stock, par value $0.00001 per shareSold 13 900 @ $33,38$464K · 2026-01-05
- Chief Financial Officer · Common Stock, par value $0.00001 per shareSold 31 961 @ $32,30$1,0M · 2026-01-05
- Director · Common Stock, par value $0.00001 per shareOther 3 150 · 2026-01-02
- Chief Financial Officer · Common Stock, par value $0.00001 per shareOther 41 000 · 2026-01-02
- Chief Operating Officer · Common Stock, par value $0.00001 per shareOther 41 000 · 2026-01-02
- Chief Operating Officer · Common Stock, par value $0.00001 per shareOther 32 049 · 2026-01-02
- Director, President & CEO · Common Stock, par value $0.00001 per shareOther 78 400 · 2026-01-02
- Director, President & CEO · Common Stock, par value $0.00001 per shareOther 224 080 · 2026-01-02
Short positioning
Geographic breakdown
Intel & risk
4 tracked-field change(s) detected vs prior analysis; max severity: medium.
- Dilution risk— → lowlow
- Liquidity risk— → lowlow
- Activity— → Unclassifiedmedium
- Economic sector— → Unclassifiedmedium
- Narrative— → —medium
- Conclusion— → —medium
Evidence & claims
From filings & derived data- Revenue (annual): USD 0Unknown
- Operating income (annual): USD -393.34MUnknown
- Operating cash flow (annual): USD -278.69MUnknown
- R&D expense (annual): USD 344.95MUnknown
- Cash & equivalents (annual): USD 165.81MUnknown
- Shares outstanding (annual): 114.79MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -3Unknown
- EPS (basic) (annual): USD-PER-SHARES -3Unknown
- Net income (annual): USD -359.64MUnknown
- Total liabilities (annual): USD 76.67MUnknown
- Current assets (annual): USD 715.6MUnknown
- Shareholders' equity (annual): USD 639.06MUnknown
- Current liabilities (annual): USD 76.67MUnknown
- Total operating expenses (annual): USD 393.34MUnknown
- Total assets (annual): USD 715.73MUnknown
- Pre-tax income (annual): USD -359.64MUnknown
- Current ratio (FY 2025-12-31): 9.33xDerived (calculated)
- Return on assets (FY 2025-12-31): -50.2%Derived (calculated)
- Return on equity (FY 2025-12-31): -56.3%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 173.4%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -21.2%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -27.4%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 239.4%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -160.6%Derived (calculated)